OMER: חוב כולל להון Omeros Corp.

Omeros Corporation (OMER) develops therapeutic antibodies to combat rare neurological pathologies, leveraging long-term patent protection and stable demand. This chart of the total debt-to-equity ratio, which stands at 0.00, complements data on the development of unique therapies for kidney and blood diseases via immune enzyme management. The prospects for Omeros Corporation (OMER) depend on regulatory approval of its key products.

Omeros Corporation maintains a diversified clinical trial portfolio that ensures a steady flow of liquidity, minimizing the need for borrowed funds. This ratio compares total liabilities to the market value of equity, determining the business's degree of financial autonomy. The metric measures the company's dependence on external borrowing relative to its net assets. Low values confirm balance sheet resilience and the predictability of cash flows. Analyzing the company's financial leverage history allows for an assessment of debt load risk.